Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082250 · ClinicalTrials.gov registry record · Phase 1
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01082250 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 52 participants.
The verdict
NCT01082250, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
Interventions
- DRUG Lurasidone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01082250
The ClinicalTrials.gov registry entry for NCT01082250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lurasidone HCl is the first listed.
NCT01082250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01082250 about?
NCT01082250 is a clinical study titled "The Bioequivalence Of Two Different Lurasidone Formulations In Patients". A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
What is the current status of trial NCT01082250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2008-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT01082250?
The interventions under investigation include: Lurasidone HCl (DRUG).
Who is sponsoring clinical trial NCT01082250?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.